Role of coagulation and pulmonary xenograft injury

凝血和肺异种移植损伤的作用

基本信息

  • 批准号:
    6608785
  • 负责人:
  • 金额:
    $ 4.81万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2002
  • 资助国家:
    美国
  • 起止时间:
    2002-07-08 至 2004-07-07
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Our purpose is to determine the role of coagulation system activation and inadequate regulation within the pulmonary xenograft on endothelial cell activation, inflammatory augmentation and pulmonary xenograft injury. Initiation of the coagulation system coincides with the acute lung injury that is caused by a) ischemia-reperfusion b) complement activation c) probably antibody binding and d) the pro-coagulant and anti-fibrinolytic actions of pulmonary macrophages. Coagulation system dysregulation allows for uncontrolled acceleration of coagulation with cascading effects on the endothelial cell and the inflammatory system. Strategies to decrease the initiating events leading to activation of the coagulation system are our focus. We plan to 1) deplete the pulmonary macrophages by repetitive administration of intravenous liposomal clodronate to determine their role in initiation of the diffuse intravascular coagulation, endothelial cell activation, and pulmonary xenograft injury 2) determine the importance of xenoreactive antibody binding to Gala1 -3Gal epitopes in pulmonary xenograft injury by depleting antibody in the absence of complement activation using a-gal trisaccharide-PEG conjugates in conjunction with complement inhibition using C1-inhibitor and anti- C5a and 3) inhibit and regulate the coagulation system through the use of inhibition of tissue factor dependent activation of factors IX and X using TFPI or ASIS, and inhibition of factor VIlla and Va by Activated Protein C to assess the effects on endothelial cell function, inflammatory system activation and xenograft function.
描述(由申请方提供):我们的目的是确定肺异种移植物内凝血系统激活和调节不足对内皮细胞激活、炎症增强和肺异种移植物损伤的作用。凝血系统的启动与急性肺损伤一致,急性肺损伤由a)缺血-再灌注B)补体激活c)可能的抗体结合和d)肺巨噬细胞的促凝血和抗纤维蛋白溶解作用引起。凝血系统失调允许不受控制的凝血加速,对内皮细胞和炎症系统产生级联效应。减少导致凝血系统激活的起始事件的策略是我们的重点。我们计划:1)通过重复静脉注射氯膦酸脂质体来消耗肺巨噬细胞,以确定它们在引发弥漫性血管内凝血、内皮细胞活化、和肺异种移植损伤2)通过在不存在补体激活的情况下使用α-半乳糖三糖消耗抗体来确定与Gala 1 - 3 Gal表位结合的异种反应性抗体在肺异种移植损伤中的重要性-PEG缀合物与使用C1-抑制剂和抗-C5 a的补体抑制结合,和3)通过使用TFPI或ASIS抑制因子IX和X的组织因子依赖性活化,以及通过活化蛋白C抑制因子VIIa和Va来抑制和调节凝血系统,以评估对内皮细胞功能、炎症系统活化和异种移植物功能的影响。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Economic evaluation of everolimus vs. azathioprine at one year after de novo heart transplantation.
从头心脏移植后一年依维莫司与硫唑嘌呤的经济评估。
  • DOI:
    10.1111/j.1399-0012.2004.00312.x
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    2.1
  • 作者:
    Radeva,JasminaI;Reed,ShelbyD;Kalo,Zoltan;Kauf,TeresaL;Cantu3rd,Edward;Cretin,Nathalie;Schulman,KevinA
  • 通讯作者:
    Schulman,KevinA
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

EDWARD CANTU其他文献

EDWARD CANTU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('EDWARD CANTU', 18)}}的其他基金

Objective lung assessment tools for improved organ use in lung transplantation
用于改善肺移植中器官使用的客观肺部评估工具
  • 批准号:
    10297778
  • 财政年份:
    2021
  • 资助金额:
    $ 4.81万
  • 项目类别:
Objective lung assessment tools for improved organ use in lung transplantation
用于改善肺移植中器官使用的客观肺部评估工具
  • 批准号:
    10609043
  • 财政年份:
    2021
  • 资助金额:
    $ 4.81万
  • 项目类别:
Objective lung assessment tools for improved organ use in lung transplantation
用于改善肺移植中器官使用的客观肺部评估工具
  • 批准号:
    10447648
  • 财政年份:
    2021
  • 资助金额:
    $ 4.81万
  • 项目类别:
Advanced diagnostics for donor lung assessment and ex vivo lung perfusion candidate selection
用于供体肺评估和离体肺灌注候选选择的高级诊断
  • 批准号:
    9353860
  • 财政年份:
    2016
  • 资助金额:
    $ 4.81万
  • 项目类别:
Advanced diagnostics for donor lung assessment and ex vivo lung perfusion candidate selection
用于供体肺评估和离体肺灌注候选选择的高级诊断
  • 批准号:
    9223995
  • 财政年份:
    2016
  • 资助金额:
    $ 4.81万
  • 项目类别:
Lung Transplant donor: prediction, evaluation, and mechanism
肺移植供体:预测、评估和机制
  • 批准号:
    8424616
  • 财政年份:
    2013
  • 资助金额:
    $ 4.81万
  • 项目类别:
Lung Transplant donor: prediction, evaluation, and mechanism
肺移植供体:预测、评估和机制
  • 批准号:
    8609591
  • 财政年份:
    2013
  • 资助金额:
    $ 4.81万
  • 项目类别:
Role of coagulation and pulmonary xenograft injury
凝血和肺异种移植损伤的作用
  • 批准号:
    6551394
  • 财政年份:
    2002
  • 资助金额:
    $ 4.81万
  • 项目类别:

相似海外基金

EPIphANy (Evaluation of Pharmacological Interactions with Anticoagulants in caNcer patients) program - prostate cancer cohort
EPIPHANy(癌症患者抗凝药理相互作用的评估)计划 - 前列腺癌队列
  • 批准号:
    479295
  • 财政年份:
    2023
  • 资助金额:
    $ 4.81万
  • 项目类别:
    Operating Grants
Inhibitors of Human Factor XIIIa as New Anticoagulants
人类因子 XIIIa 抑制剂作为新型抗凝剂
  • 批准号:
    10629057
  • 财政年份:
    2023
  • 资助金额:
    $ 4.81万
  • 项目类别:
Establishment of comprehensive monitoring of direct oral anticoagulants (DOACs) for clinical application
建立临床应用直接口服抗凝剂(DOAC)综合监测体系
  • 批准号:
    23K06906
  • 财政年份:
    2023
  • 资助金额:
    $ 4.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Interactions of Enzyme-Inducing Antiepileptic Drugs with Direct-Acting Oral Anticoagulants: Risk of Thromboembolic Events
酶诱导抗癫痫药物与直接作用口服抗凝剂的相互作用:血栓栓塞事件的风险
  • 批准号:
    10605482
  • 财政年份:
    2023
  • 资助金额:
    $ 4.81万
  • 项目类别:
The Comparative Effectiveness and Safety of Oral Anticoagulants in Patients with Cirrhosis and Atrial Fibrillation
口服抗凝药对肝硬化合并心房颤动患者的有效性和安全性比较
  • 批准号:
    10559071
  • 财政年份:
    2023
  • 资助金额:
    $ 4.81万
  • 项目类别:
Search for indicators of blood levels of directly inhibitory oral anticoagulants in coagulation tests using artificial intelligence
使用人工智能在凝血测试中搜索直接抑制性口服抗凝剂的血液水平指标
  • 批准号:
    22K07388
  • 财政年份:
    2022
  • 资助金额:
    $ 4.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Bleeding on Direct Oral Anticoagulants: Identification of Genetic Risk Factors and a Polygenic Predictive Score in Patients with Atrial Fibrillation
直接口服抗凝剂导致的出血:房颤患者遗传风险因素的鉴定和多基因预测评分
  • 批准号:
    10536789
  • 财政年份:
    2022
  • 资助金额:
    $ 4.81万
  • 项目类别:
Study on proper use of oral anticoagulants combined with 5-fluorouracil
口服抗凝药联合5-氟尿嘧啶正确使用研究
  • 批准号:
    22K06743
  • 财政年份:
    2022
  • 资助金额:
    $ 4.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Benchmarking a point-of-care test kit for detection of direct-oral anticoagulants
用于检测直接口服抗凝剂的即时检测试剂盒的基准测试
  • 批准号:
    461790
  • 财政年份:
    2022
  • 资助金额:
    $ 4.81万
  • 项目类别:
    Operating Grants
Direct oral anticoagulants and the risk of colorectal and pancreatic cancers: a population-based cohort study.
直接口服抗凝剂与结直肠癌和胰腺癌的风险:一项基于人群的队列研究。
  • 批准号:
    474475
  • 财政年份:
    2022
  • 资助金额:
    $ 4.81万
  • 项目类别:
    Studentship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了